Skip to main content
Caplight Logo









Walden Biosciences

Walden Biosciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://waldenbiosciences.com

Last Round

Series A

Oct 6, 2020

Total Funding Raised

$51M

Company Overview

Walden Biosciences is a biotechnology company that develops targeted therapies for kidney diseases, including chronic kidney disease and acute kidney injury.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologykidney diseasepodocyte healthdrug discoverymonoclonal antibodysmall molecule inhibitorclinical-stage biotechFSGSfocal segmental glomerulosclerosisdiabetic kidney diseaserenal therapynephrology biotechdrug pipelinebiopharmatherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Walden Biosciences Comparables

Compare Walden Biosciences with similar companies based on industry and business-model similarity.

Walden Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
River 3 Renal Corp.
86%
Purespring Therapeutics
77%
Dimerix Ltd
76%

Walden Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 6, 2020

Key People

Founding team and executive leadership

Diane Vrattos

Manager, Executive Office of President & CEO

Executive Team

Julie Morando

Manager, Executive Office of President and Chief Executive Officer

Executive Team

Curt Dewan

Chief Financial Officer

Executive Team

Walden Biosciences Investors

Notable investors and investment history

Walden Biosciences investors
InvestorRounds
UCB VenturesSeries A
UCB VenturesSeries A
ARCH Venture PartnersSeries A
ATEM CapitalSeries A
Pandect BioventuresSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 28, 2025

    Howard Mayer, M.D. appointed to the Board of Directors.

Walden Biosciences Filings

Explore SEC and related filing metadata, where available.

Walden Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Walden Biosciences's valuation, stock price, and market status.

Is Walden Biosciences a public or private company?

Walden Biosciences is a private company.

What is the current stock price of Walden Biosciences?

Walden Biosciences is a private company, so its shares have no public market price. Caplight tracks Walden Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Walden Biosciences worth (valuation)?

Valuation information for Walden Biosciences is not publicly available.

Can I buy Walden Biosciences stock?

Walden Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Walden Biosciences's last funding round?

Walden Biosciences's most recent funding round was Series A on October 6, 2020.

Who are the main investors in Walden Biosciences?

Key investors in Walden Biosciences include UCB Ventures, UCB Ventures, ARCH Venture Partners.

Will Walden Biosciences IPO soon?

No public IPO plans have been announced for Walden Biosciences.

How can I track Walden Biosciences secondary market activity?

Caplight tracks bids, offers, and trades in Walden Biosciences's shares on secondary markets.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range16
Year Founded2020
Last FundingOct 6, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?